Sutro Biopharma Raises $16.5M in Series C Second Tranche

Sutro Biopharma, a San Francisco-based company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, has closed a $16.5m second tranche of its Series C financing.

The financing was led by Skyline Ventures, with participation from Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.

Founded in 2003 and led by CEO William Newell, Sutro has developed biochemical synthesis technology, which allows the rapid and systematic exploration of many protein drug variants to identify drug candidates. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotech companies in the discovery and development of novel protein therapeutics.



Join the discussion